Kennedy Hearing Repeatedly Raised FDA Actions
FDA was a recurring point of reference during a 4/16 House budget hearing featuring HHS secretary Robert F. Kennedy Jr., as lawmakers pressed the administration on drug regulation, approval timelines, and the broader competitiveness of U.S. biomedical policy. While the hearing was centered on HHS budget priorities and health system oversight, exchanges repeatedly returned to FDA performance as members of Congress used the agency as a benchmark for regulatory efficiency and drug development outcomes.
During questioning, at least one lawmaker criticized what was described as “bungled drug reviews” at FDA, arguing that regulatory delays and perceived inconsistencies have contributed to a broader shift of parts of the drug development pipeline outside the U.S. The comment was framed in the context of concerns about whether current regulatory structures are keeping pace with global pharmaceutical innovation.
Kennedy responded by defending FDA’s recent operational performance, pointing to continued approval activity across drugs, generics, and medical devices. His remarks positioned the agency as still functioning at a steady regulatory pace, even amid broader debates about efficiency and oversight. Kennedy expressed support for FDA commissioner Marty Makary’s recent handling of FDA’s second rejection of Replimune’s melanoma therapy, referencing a Wall Street Journal editorial that had criticized the agency’s complete response letter. He said Makary “made the right call” in declining approval, arguing that the decision was appropriate based on the available evidence.
He went on to say that Makary has faced significant pushback as a result of industry influence, suggesting that powerful pharmaceutical interests can shape both political and media narratives.
As expected, vaccine policy became one of the most contentious topics of the hearing, with lawmakers pressing secretary Kennedy on recent shifts in federal immunization strategy and the implications for public health. House members raised concerns about declining vaccination coverage in several jurisdictions and pointed to ongoing measles outbreaks as evidence that federal messaging and program changes may be contributing to uneven uptake of routine childhood vaccines. Attention also centered on whether recent adjustments to advisory processes and program priorities at HHS agencies, including the CDC, could be affecting the consistency of vaccine recommendations across the country.
Kennedy defended the administration’s approach, arguing that vaccine policy is being reassessed within a broader effort to recalibrate federal public health guidance around updated risk-benefit frameworks and increased emphasis on transparency. He emphasized that HHS continues to support access to vaccines while seeking to ensure that recommendations reflect evolving scientific evidence and individual health considerations. In doing so, he framed the changes less as a retreat from immunization policy and more as a restructuring of how vaccine guidance is evaluated and communicated.
The exchange highlighted a broader divide between lawmakers concerned about erosion of longstanding federal vaccine consensus and the administration’s effort to reorient public health policy toward what it describes as greater flexibility and responsiveness to emerging data and public confidence challenges.